Denali Therapeutics Inc Stock Research

Market Summary

USD31.47+0.94

Market Closed

3.08%

DNLI Alerts

2 major insider sales recently.

DNLI Stock Price

DNLI RSI Chart

DNLI Valuation

Market Cap

3.9B

Price/Earnings (Trailing)

-12.88

Price/Sales (Trailing)

32.03

Price/Free Cashflow

-15.36

DNLI Price/Sales (Trailing)

DNLI Profitability

Return on Equity

-37.29%

Return on Assets

-24.65%

Free Cashflow Yield

-6.51%

DNLI Fundamentals

DNLI Revenue

Revenue (TTM)

112.4M

Revenue Y/Y

128.78%

Revenue Q/Q

24.53%

DNLI Earnings

Earnings (TTM)

-302.6M

Earnings Y/Y

-22.12%

Earnings Q/Q

-75.7%

Price Action

52 Week Range

20.2439.43

(Low)(High)

Last 7 days

8.3%

Last 30 days

18.3%

Last 90 days

6.3%

Trailing 12 Months

0.1%

DNLI Financial Health

Current Ratio

3.16

DNLI Investor Care

Shares Dilution (1Y)

1.69%

Diluted EPS (TTM)

-2.47

Peers (Alternatives to Denali Therapeutics)

View All Peers In Detail

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
AMGN	135.3B	26.3B	-2.97%	16.81%	19.8	5.14	2.18%	21.86%
GILD	105.0B	27.1B	-0.99%	30.15%	31.49	3.87	-1.26%	-54.91%
MRNA	73.3B	21.4B	7.28%	27.41%	6.23	3.43	80.80%	66.62%
BIIB	41.9B	10.4B	5.85%	32.49%	14.62	4.04	-6.64%	85.32%
NBIX	10.4B	1.4B	-8.79%	49.41%	178.74	7.49	29.86%	-86.92%
MID-CAP
DNLI	3.9B	-	18.31%	0.06%	-12.88	32.03	-41.50%	-1123.42%
BEAM	3.2B	-	23.33%	-24.11%	-10.12	59.51	215916.67%	21.41%
SMALL-CAP
RCUS	1.7B	432.8M	17.41%	-21.00%	20.97	3.87	1042.97%	128.67%
BBIO	1.4B	-	35.16%	1.79%	-2.74	20.84	745.14%	12.80%
REPL	1.3B	3.1M	-3.43%	39.57%	-8.78	417.83	7.05%	-46.74%
NVAX	886.0M	1.8B	24.61%	-84.52%	-0.67	0.48	53.41%	-22.97%
FATE	574.9M	69.0M	-39.96%	-83.45%	-1.96	8.33	26.22%	-49.52%
SGMO	565.8M	112.1M	28.78%	-35.14%	-3.18	5.05	3.26%	1.99%
VXRT	142.4M	-	42.67%	-74.19%	-1.36	418.24	-71.03%	-64.56%
IBIO	6.7M	-	67.66%	-93.12%	-0.11	3.21	0.51%	-141.69%

Financials for Denali Therapeutics

Income Statement (Last 12 Months)					(In Millions)
Description	(%) Q/Q	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3
Revenue	-100.0%	null	112	83	49	120
Operating Expenses	5.0%	423	403	374	344	328
S&GA Expenses	4.6%	89	85	83	79	75
R&D Expenses	5.1%	334	318	291	265	252
Net Income	-6.6%	-302.57	-283.86	-285.76	-290.58	30
Net Income Margin	-6.6%	-2.69*	-2.53*	-3.45*	-5.97*	-
Free Cahsflow	-8.5%	-253.58	-233.80	-243.00	-219.89	-

* denotes actual numbers (not divided by Millions)

Balance Sheet					(In Millions)
Description	(%) Q/Q	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3
Assets	-5.0%	1,228	1,292	1,321	1,404	1,450
Current Assets	2.1%	1,139	1,115	988	897	1,056
Cash Equivalents	-23.5%	119	155	105	293	396
Net PPE	7.7%	42	39	38	39	40
Liabilities	2.0%	416	408	403	442	438
Current Liabilities	3.6%	361	348	341	378	54
Shareholder's Equity	-8.3%	811	884	918	962	1,012
Retained Earnings	-13.4%	-872.31	-769.01	-710.22	-645.00	-569.73
Additional Paid-In Capital	1.8%	1,694	1,664	1,636	1,608	1,581
Accumulated Depreciation	-	29	-	-	-	-
Shares Outstanding	0.5%	124	123	123	122	122

* denotes actual numbers (not divided by Millions)

Cashflow (Last 12 Months)					(In Millions)
Description	(%) Q/Q	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3
Cashflow From Operations	-7.0%	-237.55	-221.93	-233.26	-211.39	368
Share Based Compensation	3.8%	97	93	90	85	77
Cashflow From Investing	55.6%	-54.58	-123.00	-114.10	-21.63	-348.22
Cashflow From Financing	12.8%	16	14	17	19	24

Risks for DNLI

What is the probability of a big loss on DNLI?

100%

Probability that Denali Therapeutics stock will be more than 20% underwater in next one year

91.2%

Probability that Denali Therapeutics stock will be more than 30% underwater in next one year.

54.6%

Probability that Denali Therapeutics stock will be more than 40% underwater in next one year.

*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does DNLI drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Denali Therapeutics was unfortunately bought at previous high price.

Drawdowns

Returns for DNLI

Cumulative Returns on DNLI

7.2%

5-Year Cumulative Returns

8.2%

3-Year Cumulative Returns

What are the long-term rolling returns for DNLI?

FIve years rolling returns for Denali Therapeutics.

Annualized Returns

Which funds bought or sold DNLI recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
2023-01-26	STRS OHIO	unchanged	-	-97,000	937,000	-%
2023-01-25	Lindbrook Capital, LLC	added	28.16	873	9,873	-%
2023-01-25	Clarius Group, LLC	unchanged	-	-751,000	7,247,000	0.65%
2023-01-24	BAILLIE GIFFORD & CO	added	2.75	-31,133,000	420,472,000	0.44%
2023-01-23	Allspring Global Investments Holdings, LLC	reduced	-2.14	-10,840	90,160	-%
2023-01-18	Activest Wealth Management	unchanged	-	-357	3,643	-%
2023-01-18	EXCHANGE TRADED CONCEPTS, LLC	added	18.75	5,000	72,000	-%
2023-01-17	ARTHUR M. COHEN & ASSOCIATES, LLC	unchanged	-	-44,450	426,550	0.12%
2023-01-17	Ronald Blue Trust, Inc.	added	33.33	-	-	-%
2023-01-13	Allworth Financial LP	unchanged	-	222	222	-%

Latest Funds Activity

Are funds buying DNLI calls or puts?

Calls

Puts

Are funds bullish or bearish(Calls - Puts)?

Net Call Options

No. of funds that own DNLI

No. of Funds

DNLI Alerts

2 major insider sales recently.

Denali Therapeutics News

Schedule 13G FIlings of Denali Therapeutics

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Jan 20, 2023	baillie gifford & co	11.13%	15,119,474	SC 13G/A
Feb 14, 2022	bratton douglas k	6.4%	7,845,189	SC 13G/A
Feb 14, 2022	price t rowe associates inc /md/	3.7%	4,635,433	SC 13G/A
Feb 09, 2022	vanguard group inc	6.68%	8,161,530	SC 13G/A
Feb 09, 2022	fmr llc	-	0	SC 13G/A
Feb 08, 2022	arch venture fund viii, l.p.	-	0	SC 13G/A
Feb 03, 2022	blackrock inc.	6.6%	8,110,822	SC 13G/A
Jan 18, 2022	baillie gifford & co	12.33%	15,056,381	SC 13G/A
Feb 16, 2021	flagship ventures fund v, l.p.	2.2%	2,730,263	SC 13G/A
Feb 16, 2021	price t rowe associates inc /md/	5.3%	6,464,826	SC 13G

DNLI Fair Value

Recent SEC filings of Denali Therapeutics

View All Filings

Date Filed	Form Type	Document
Jan 20, 2023	SC 13G/A	Major Ownership Report
Jan 19, 2023	4	Insider Trading
Jan 10, 2023	4	Insider Trading
Jan 09, 2023	4	Insider Trading
Jan 09, 2023	4	Insider Trading
Jan 09, 2023	4	Insider Trading
Jan 09, 2023	4	Insider Trading
Jan 09, 2023	4/A	Insider Trading
Jan 09, 2023	8-K	Current Report
Jan 05, 2023	4	Insider Trading

Latest Insider Trading transactions for DNLI

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
2023-01-17	Schuth Alexander O.	acquired	52,800	5.28	10,000	cofo and secretary
2023-01-17	Schuth Alexander O.	sold	-295,339	29.5339	-10,000	cofo and secretary
2023-01-09	Ho Carole	sold	-41,552.3	28.48	-1,459	chief medical officer
2023-01-06	Ho Carole	sold	-41,600.2	28.67	-1,451	chief medical officer
2023-01-05	Schuth Alexander O.	sold	-74,967.8	28.44	-2,636	cofo and secretary
2023-01-05	Krognes Steve E.	sold	-84,466.8	28.44	-2,970	-
2023-01-05	Watts Ryan J.	sold	-136,512	28.44	-4,800	president and ceo
2023-01-05	Ho Carole	sold	-74,967.8	28.44	-2,636	chief medical officer
2023-01-04	Schuth Alexander O.	sold	-83,574.4	28.7	-2,912	cofo and secretary
2023-01-04	Ho Carole	sold	-83,574	28.69	-2,913	chief medical officer

About Denali Therapeutics

Ryan J. Watts

www.denalitherapeutics.com

380

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease. The company also develops DNL310 that is in Phase I/II clinical trials for the treatment of hunter syndrome; DNL343, which is in phase 1 clinical trial the treatment of amyotrophic lateral sclerosis (ALS); AR443820/DNL788 completed a phase I clinical trial for the treatment of ALS, multiple sclerosis (MS), and Alzheimer's disease; and SAR443122/DNL758, which is in phase II clinical trial for the treatment of cutaneous lupus erythematosus. It has collaboration agreement with Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene; and a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG. to develop antisense therapies in the field of neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

DNLI Income Statement

2022-09-30

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands

3 Months Ended

9 Months Ended

Sep. 30, 2022

Sep. 30, 2021

Sep. 30, 2022

Sep. 30, 2021

Collaboration revenue:

Collaboration revenue from customers

^[1]

$ 184

$ 5,285

$ 94,805

$ 36,143

Other collaboration revenue

3,375

Total collaboration revenue

3,559

5,285

98,180

36,147

Operating expenses:

Research and development

^[2]

87,786

71,559

266,621

197,477

General and administrative

23,259

19,319

66,959

57,300

Total operating expenses

111,045

90,878

333,580

254,777

Loss from operations

(107,486)

(85,593)

(235,400)

(218,630)

Interest and other income, net

4,187

1,005

8,114

3,310

Loss before income taxes

(103,299)

(84,588)

(227,286)

(215,320)

Income tax expense

(27)

Net loss

(103,299)

(84,588)

(227,313)

(215,320)

Other comprehensive income (loss):

Net unrealized gain (loss) on marketable securities, net of tax

421

(153)

(9,354)

(276)

Comprehensive loss

$ (102,878)

$ (84,741)

$ (236,667)

$ (215,596)

Net loss per share, basic (usd per share)

$ (0.84)

$ (0.69)

$ (1.85)

$ (1.77)

Net loss per share, diluted (usd per share)

$ (0.84)

$ (0.69)

$ (1.85)

$ (1.77)

Weighted average number of shares outstanding, basic (in shares)

123,473,390

121,742,067

123,054,889

121,309,197

Weighted average number of shares outstanding, diluted (in shares)

123,473,390

121,742,067

123,054,889

121,309,197

[1]	Includes related-party collaboration revenue from a customer of $0.2 million and $2.9 million for the three and nine months ended September 30, 2022, respectively, and $0.9 million and $2.5 million for the three and nine months ended September 30, 2021, respectively.
[2]	Includes expense for cost sharing payments due to a related party of $1.4 million and $3.8 million for the three and nine months ended September 30, 2022, respectively, and an offset to expense from related-party cost sharing reimbursements of $1.2 million and $5.3 million for the three and nine months ended September 30, 2021, respectively.

DNLI Balance Sheet

2022-09-30

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 118,615	$ 293,477
Short-term marketable securities	987,440	571,930
Cost sharing reimbursements due from related party	0	1,226
Prepaid expenses and other current assets	32,471	30,601
Total current assets	1,138,526	897,234
Long-term marketable securities	0	425,449
Property and equipment, net	41,692	38,865
Operating lease right-of-use assets	31,271	30,743
Other non-current assets	16,117	11,871
Total assets	1,227,606	1,404,162
Current liabilities:
Accounts payable	7,539	4,779
Cost sharing payments due to related party	1,443	0
Accrued compensation	13,253	19,013
Accrued clinical and other research & development costs	21,701	15,887
Accrued manufacturing costs	16,732	9,955
Other accrued costs and current liabilities	2,395	2,857
Operating lease liabilities, current	7,068	5,453
Related-party contract liability, current	290,516	292,386
Contract liabilities, current	23	27,915
Total current liabilities	360,670	378,245
Related-party contract liability, less current portion	276	1,295
Contract liabilities, less current portion	0	3,398
Operating lease liabilities, less current portion	54,978	58,554
Other non-current liabilities	379	379
Total liabilities	416,303	441,871
Commitments and contingencies (Note 6)
Stockholders' equity:
Convertible preferred stock, $0.01 par value; 40,000,000 shares authorized as of September 30, 2022 and December 31, 2021; 0 shares issued and outstanding as of September 30, 2022 and December 31, 2021	0	0
Common stock, $0.01 par value; 400,000,000 shares authorized as of September 30, 2022 and December 31, 2021; 123,796,438 shares and 122,283,305 shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively	1,564	1,548
Additional paid-in capital	1,693,901	1,608,238
Accumulated other comprehensive loss	(11,853)	(2,499)
Accumulated deficit	(872,309)	(644,996)
Total stockholders' equity	811,303	962,291
Total liabilities and stockholders’ equity	$ 1,227,606	$ 1,404,162